Patients with pancreatic ductal adenocarcinoma (PDAC) usually have a dismal prognosis, and even after curative resection most patients will have disease relapse and ultimately die. Nonetheless, adjuvant chemotherapy has considerably improved the outcomes of patients who are able to undergo surgery. The PREOPANC trial provides some evidence supporting the use of neoadjuvant therapy for patients with borderline resectable PDACs but not, as claimed, for those with resectable tumours.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Personalized treatment in localized pancreatic cancer
European Surgery Open Access 02 October 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200–1210 (2004).
Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. J. Am. Med. Assoc. 304, 1073–1081 (2010).
Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018).
Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).
Versteijne, E. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J. Clin. Oncol. 38, 1763–1773 (2020).
Versteijne, E. et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.02233 (2022).
Katz, M. H. G. et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J. Clin. Oncol. 39, 377 (2021).
Ghaneh, P. et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J. Clin. Oncol. 38, 4505 (2020).
Maeda, S. et al. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Surgery https://doi.org/10.1016/j.surg.2021.10.015 (2021).
Sohal, D. P. S. et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 7, 421–427 (2021).
Acknowledgements
We acknowledge statistical advice provided by R. Jackson (Head of Statistics, Cancer Division, Liverpool Clinical Trials Centre, The University of Liverpool).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Springfeld, C., Neoptolemos, J.P. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. Nat Rev Clin Oncol 19, 285–286 (2022). https://doi.org/10.1038/s41571-022-00612-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00612-6
This article is cited by
-
Therapeutic developments in pancreatic cancer
Nature Reviews Gastroenterology & Hepatology (2024)
-
Neoadjuvant therapy for pancreatic cancer
Nature Reviews Clinical Oncology (2023)
-
Personalized treatment in localized pancreatic cancer
European Surgery (2023)
-
Preoperative evaluating early recurrence in resectable pancreatic ductal adenocarcinoma by using CT radiomics
Abdominal Radiology (2023)
-
Aktuelle systemische Therapie beim Pankreaskarzinom
Die Onkologie (2023)